Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 14/20 | 0.63 |
| ▸ | LMNA | P02545 | 5/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.61 |
| ▸ | NPC1 | O15118 | 6/20 | 0.61 |
| ▸ | RAB9A | P51151 | 6/20 | 0.61 |
| ▸ | MAPT | P10636 | 5/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.61 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.61 |
| ▸ | RELA | Q04206 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30059210 | 0.83 | NPC1 (0.66) | TP53LMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL2496897 | 0.82 | TP53 (0.68) | TP53LMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL22615087 | 0.79 | TP53 (0.59) | TP53LMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL3668799 | 0.78 | TP53 (0.70) | TP53LMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL12692390 | 0.78 | TP53 (0.70) | TP53LMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL29740253 | 0.78 | TP53 (0.70) | TP53LMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL12721714 | 0.78 | TP53 (0.70) | TP53LMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL12692486 | 0.78 | TP53 (0.70) | TP53LMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL2745663 | 0.77 | MAPT (0.71) | TP53LMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL969616 | 0.76 | NPC1 (0.66) | TP53LMNASMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2167508-A1 | COMPOUNDS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY | Summit Corporation Plc (GB) | 2010-03-31 | — | — | EP | claimed |
| WO-2009013477-A1 | COMPOUNDS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2009-01-29 | — | — | WO | claimed |
| US-20140329863-A1 | NOVEL ANTIPRION COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329863-A1 | NOVEL ANTIPRION COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-11-06 | — | — | US | disclosed |
| WO-2013033037-A2 | NOVEL ANTIPRION COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-03-07 | — | — | WO | disclosed |
| EP-2167508-A1 | COMPOUNDS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY | Summit Corporation Plc (GB) | 2010-03-31 | — | — | EP | disclosed |
| WO-2009013477-A1 | COMPOUNDS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2009-01-29 | — | — | WO | disclosed |
| US-7351481-B2 | electrical stability, better charge transporting capability, a high glass transition temperature, and does not crystallize; high-efficiency, low-voltage, high-luminance, long-lifespan; durability; color purity | SAMSUNG SDI CO., LTD. (KR) | 2008-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329863-A1 | NOVEL ANTIPRION COMPOUNDS | PRNP, PSEN1, PSEN2 | TP53 4563/4885LMNA 928/4885SMN1; SMN2 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.